NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Purchases $167,388.00 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 8,584 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was bought at an average cost of $19.50 per share, for a total transaction of $167,388.00. Following the transaction, the director now owns 3,022,153 shares of the company's stock, valued at $58,931,983.50. The trade was a 0.28% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

NewAmsterdam Pharma Trading Down 1.6%

Shares of NASDAQ:NAMS traded down $0.29 on Thursday, hitting $18.20. The company had a trading volume of 633,421 shares, compared to its average volume of 694,190. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -9.68 and a beta of -0.03. The stock has a 50 day moving average price of $18.39 and a 200 day moving average price of $20.82. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. Sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently made changes to their positions in NAMS. Deerfield Management Company L.P. Series C grew its stake in shares of NewAmsterdam Pharma by 378.4% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock valued at $110,879,000 after acquiring an additional 3,412,590 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock valued at $409,052,000 after purchasing an additional 3,061,224 shares during the period. Wellington Management Group LLP grew its position in shares of NewAmsterdam Pharma by 2,410.4% during the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after purchasing an additional 2,222,900 shares in the last quarter. Capital International Investors bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $53,007,000. Finally, Alliancebernstein L.P. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $47,752,000. Institutional investors and hedge funds own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NAMS. Cantor Fitzgerald started coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price target on the stock. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Citigroup began coverage on shares of NewAmsterdam Pharma in a research report on Tuesday. They set a "buy" rating and a $42.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Finally, Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 10th. They set a "buy" rating and a $44.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.89.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.